emDOCs.net Emergency Medicine (EM) Podcast
Episode 113: Immune Checkpoint Inhibitor Adverse Events
Jan 27, 2025
Dive into the world of immune checkpoint inhibitors in cancer therapy. This discussion reveals their fascinating impact on the immune system and the various adverse events they can trigger across organ systems. Learn about essential management strategies and the critical role of early intervention to prevent complications. It's a deep yet engaging examination of a cutting-edge topic in medicine that could change patient outcomes significantly!
17:17
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Immune checkpoint inhibitors improve cancer treatment by enhancing T-cell function, but their use can lead to significant adverse events within months from initiation.
- Management of complications from immune checkpoint inhibitors, like colitis and pneumonitis, requires interdisciplinary collaboration with oncologists and specialists for effective patient care.
Deep dives
Understanding Immune Checkpoint Inhibitors
Immune checkpoint inhibitors are a new class of cancer therapies that enhance T-cell function by blocking inhibitory signals that cancer cells use to suppress immune responses. These monoclonal antibodies target various cancers, including melanoma and lung cancer, helping improve patient outcomes significantly. There are four main classes of these inhibitors—anti-CTLA, anti-PD, anti-PD, and anti-LAG—with several drugs currently under development. However, the use of these therapies carries a risk of adverse events, with the likelihood varying based on the specific medication and the patient's unique treatment history.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
